Solid Tumors

Undefeated

I’m sure every cancer survivor feels this way, but my diagnosis, in 1997, of stage III germ cell testicular cancer couldn’t have come at a worse time in my life. I was nearing the end of a 60-city tour...

Symptom Management

Physician-Patient Partnership Is Key to Recognizing and Managing Side Effects of Immune Checkpoint Inhibitors

“Immunotherapy has a completely different side-effect profile than chemotherapy, and that has caught physicians off guard,” noted Drew Pardoll, MD, PhD, in an article...

Lymphoma

BTK Inhibitor in Relapsed or Refractory Mantle Cell Lymphoma

A phase II study (ACE-LY-004) reported in The Lancet by Michael Wang, MD, of The University of Texas MD Anderson Cancer Center, and colleagues showed durable responses...


Advertisement
Lung Cancer

FDA Approves Osimertinib for First-Line Treatment of Metastatic NSCLC With Most Common EGFR Mutations

On April 18, the U.S. Food and Drug Administration approved osimertinib for the first-line treatment of patients with metastatic non–small cell lung cancer whose tumors have epidermal growth factor receptor....

Colorectal Cancer

Following Nutrition and Exercise Guidelines May Prolong Survival in Stage III Colon Cancer

A diet high in whole grains, fruits, and vegetables—along with exercise and maintaining a healthy body weight—can improve the 5-year survival rate for patients...


More Top Stories

Prostate Cancer

James L. Gulley, MD, PhD, on Prostate Cancer: Expanding Immunotherapy Options

A Tribute to Two Amazing Scientists

Dr. Collins is Director of the National Institutes of Health. Originally posted on March 19, 2018, to the National Institutes of Health (NIH) Director’s Blog (https://directorsblog. nih.gov).  OVER THE PAST couple of weeks, we’ve lost two legendary scientists who made major contributions to our...

Advertisement

Reciprocal Risks of Lymphoid Neoplasms and Cutaneous Melanoma

In a study reported in the Journal of the National Cancer Institute, Herr et al found that patients with specific types of primary lymphoid neoplasms were at increased risk of second primary cutaneous melanoma, with the reciprocal association also being observed. Occurrence of second primary...

Colorectal Cancer

Alan P. Venook, MD, on Selecting Treatment for Advanced Colorectal Cancer

2018 Gastrointestinal Cancers Symposium

The 2018 Gastrointestinal Cancers Symposium is supported by ASCO, the American Society of Radiation Oncology, the Society of Surgical Oncology, and the AGA Institute.  Over 3,700 physicians, researchers, and allied health-care professionals attended the meeting. Photos by © ASCO/Todd Buchanan...

2018 Gastrointestinal Cancers Symposium

The 2018 Gastrointestinal Cancers Symposium is supported by ASCO, the American Society of Radiation Oncology, the Society of Surgical Oncology, and the AGA Institute.  Over 3,700 physicians, researchers, and allied health-care professionals attended the meeting. Photos by © ASCO/Todd Buchanan...

FDA Approves Osimertinib for First-Line Treatment of Metastatic NSCLC With Most Common EGFR Mutations

On April 18, the U.S. Food and Drug Administration (FDA) approved osimertinib (Tagrisso) for the first-line treatment of patients with metastatic non–small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as...

Kidney Cancer

Sumanta K. Pal, MD, on RCC: Results From Two Clinical Trials

Breast Cancer

How Will ctDNA Assays Aid in Managing Breast Cancer?

CIRCULATING TUMOR DNA (ctDNA) assays are now commercially available for use in lung cancer and melanoma, where they can identify the presence of specific mutations that drive treatment selection. In breast cancer, ctDNA remains more of a research tool, but this is poised to change.  At the 2018...

Advertisement

Following Nutrition and Exercise Guidelines May Prolong Survival in Stage III Colon Cancer

A diet high in whole grains, fruits, and vegetables—along with exercise and maintaining a healthy body weight—can improve the 5-year survival rate for patients with stage III colorectal cancer, according to a new report published by Van Blarigan et al in JAMA Oncology. The findings...